• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Johnson & Johnson (NY:JNJ)

    195.93 +0.68 (+0.35%)
    Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Johnson & Johnson

    < Previous 1 2
    ...
    30 31 32 33 34 35 36 37 38
    ...
    99 100 Next >
    Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
    Via Investor Brand Network
    News headline image
    Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
    EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers. ↗
    Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
    Via Investor's Business Daily
    Topics Stocks
    News headline image
    Johnson & Johnson's Options: A Look at What the Big Money is Thinking ↗
     
    Via Benzinga
    News headline image
    In-Depth Analysis: Johnson &amp; Johnson Versus Competitors In Pharmaceuticals Industry ↗
     
    Via Benzinga
    News headline image
    Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug ↗
    Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, while also announcing a $2 billion biologics facility to support its expanding... 
    Via Benzinga
    News headline image
    Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients ↗
    Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by... 
    Via Benzinga
    News headline image
    15 Best Dividend Stocks for Lifelong Passive Income ↗
    These 15 dividend stocks can deliver stable passive income for life. 
    Via The Motley Fool
    News headline image
    2 Excellent Dividend Stocks to Buy With Less Than $200 ↗
    Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years. 
    Via The Motley Fool
    News headline image
    Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma ↗
    Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma. 
    Via Investor's Business Daily
    News headline image
    Why NYSE:JNJ provides a good dividend, while having solid fundamentals. ↗
    Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
    Via Chartmill
    News headline image
    The Latest Analyst Ratings For Johnson & Johnson ↗
     
    Via Benzinga
    News headline image
    Unpacking the Latest Options Trading Trends in Johnson & Johnson ↗
     
    Via Benzinga
    News headline image
    Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment ↗
    Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other therapies, demonstrating significant potential in treating relapsed or refractory... 
    Via Benzinga
    News headline image
    For those who appreciate value investing, NYSE:JNJ is a compelling option with its solid fundamentals. ↗
    JOHNSON & JOHNSON (NYSE:JNJ) is an undervalued gem with solid fundamentals. 
    Via Chartmill
    News headline image
    Why Masimo Stock Crushed the Market Today ↗
    The company seems to be effecting a smooth transition in its leadership. 
    Via The Motley Fool
    News headline image
    Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff ↗
    Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
    Via Benzinga
    News headline image
    2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗
    These dividend players could lift your portfolio no matter what the market is doing. 
    Via The Motley Fool
    News headline image
    10 Health Care Stocks With Whale Alerts In Today's Session ↗
     
    Via Benzinga
    News headline image
    Is Johnson & Johnson Stock a Buy? ↗
    This healthcare blue chip is making all the right moves to reward shareholders. 
    Via The Motley Fool
    News headline image
    Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
    From Beasley Allen Law Firm
    Via Business Wire
    News headline image
    Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
    From Johnson & Johnson
    Via Business Wire
    News headline image
    Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients ↗
    Johnson & Johnson's Rybrevant (amivantamab) received FDA approval for use with standard chemotherapy in advanced non-small cell lung cancer with specific EGFR mutations. 
    Via Benzinga
    News headline image
    Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease ↗
    The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic... 
    Via Benzinga
    News headline image
    2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗
    Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
    Via Investor's Business Daily
    News headline image
    2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement ↗
    This two-step strategy could set investors up with a large sum of passive income in retirement. 
    Via The Motley Fool
    News headline image
    Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug ↗
    JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the... 
    Via Benzinga
    News headline image
    Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
    These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025. 
    Via MarketBeat
    Topics Economy
    News headline image
    Time To Invest And Or Trade In Bio-Tech Stocks? ↗
    Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
    Via Talk Markets
    Topics ETFs
    News headline image
    Should You Buy Novavax Stock After This Regulatory Win? ↗
    The biotech continues to earn important wins, but is it enough? 
    Via The Motley Fool
    < Previous 1 2
    ...
    30 31 32 33 34 35 36 37 38
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.